Founded in 2014, Sydnexis Inc. is a privately held, clinical stage biopharmaceutical company based in San Diego. Sydnexis is currently evaluating its patented eyedrop formulation, SYD-101, in a Phase 3 clinical trial to decrease myopia progression in children.
Myopia is the most common eye disease in children and has experienced a dramatic increase in prevalence over the last 30 years. Once considered a benign refractive condition, even at low levels, myopia is now associated with many serious ophthalmic co-morbidities. With greater severity of myopia, the higher the risk of these ophthalmic co-morbidities later in life as well. Sydnexis was founded with the goal of developing a proprietary, stable, topical eyedrop to treat the progression of myopia in children and minimize the risk co-morbidities.